Protein / target
DNA gyrase subunit B
Protein at a glance
Biological role
DNA negative supercoiling
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state.
View complete UniProt function annotationHide complete annotation
A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state. Negative supercoiling favors strand separation, and DNA replication, transcription, recombination and repair, all of which involve strand separation. Also able to catalyze the interconversion of other topological isomers of dsDNA rings, including catenanes and knotted rings. Type II topoisomerases break and join 2 DNA strands simultaneously in an ATP-dependent manner
Subcellular location
Domains and Gene Ontology detail (10)Hide
Domains & features
Gene Ontology
- Cchromosome
- Ccytoplasm
- FATP binding
- FDNA binding
- FDNA negative supercoiling activity
- Fmetal ion binding
- PDNA topological change
- PDNA-templated DNA replication
- Presponse to antibiotic
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
DNA gyrase inhibitor
Indicated for Bacterial Infections, Cystic Fibrosis, Eye Infections, Infections
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: LEVOFLOXACIN (ANDA090722)
- Label change
Label change: LEVOFLOXACIN (ANDA200560)
- Label change
Label change: LEVOFLOXACIN (ANDA090722)
- New publicationCiprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway.
- Label change
Label change: LEVOFLOXACIN (ANDA090722)
- Label change
Label change: LEVOFLOXACIN (ANDA090722)
- Regulatory approval
Approval: Quinsair (EMA)
- Safety communication
Drug Safety Update: Levofloxacin: some indications restricted
- Regulatory approval
Approval: LEVOFLOXACIN (ANDA090722)
- Regulatory approval
Approval: LEVOFLOXACIN (ANDA200560)
- New publicationProphylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors.
- New publicationRisk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.